Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 8,236 shares, a drop of 21.3% from the March 31st total of 10,469 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 18,266 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Barinthus Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Stock Up 0.1%

Shares of BRNS traded up $0.00 during mid-day trading on Friday, reaching $0.65. The company’s stock had a trading volume of 5,564 shares, compared to its average volume of 39,901. The business has a fifty day moving average of $0.60 and a 200 day moving average of $0.76. The company has a market cap of $26.58 million, a price-to-earnings ratio of -0.40 and a beta of -0.61. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Wednesday, May 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14. On average, analysts predict that Barinthus Biotherapeutics will post -1.42 earnings per share for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Renaissance Technologies LLC lifted its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,100 shares of the company’s stock after acquiring an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.